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Antibody based positron emission tomography (immuno-PET) imaging is of increasing importance to visualize and characterize
tumor lesions. Additionally, it can be used to identify patients who may benefit from a particular therapy and monitor the therapy
outcome. In recent years the field is focused on 89Zr, a radiometal with near ideal physical and chemical properties for immuno-PET.
In this reviewwewill discuss the production of 89Zr, the bioconjugation strategies, and applications in (pre-)clinical studies of 89Zr-
based immuno-PET in oncology. To date, 89Zr-based PET imaging has been investigated in a wide variety of cancer-related targets.
Moreover, clinical studies have shown the feasibility for 89Zr-based immuno-PET to predict andmonitor treatment, which could be
used to tailor treatment for the individual patient. Further research should be directed towards the development of standardized and
robust conjugation methods and improved chelators to minimize the amount of released Zr4+ from the antibodies. Additionally,
further validation of the imaging method is required. The ongoing development of new 89Zr-labeled antibodies directed against
novel tumor targets is expected to expand applications of 89Zr-labeled immuno-PET to a valuable method in the medical imaging.
1. Introduction
Molecular biomarkers can be used to monitor, image, and
measure biological processes at molecular or cellular level.
Different types of biomarkers are known, including diagnos-
tic, prognostic, and predictive biomarkers, or a combina-
tion of these [1]. Extensive research has been done on the
development of molecular imaging biomarkers in the field of
cancer. This has led to tools that can be used to visualize and
characterize tumor lesions. An advantage of using molecular
imaging agents is the noninvasive nature of these procedures,
whereas in conventional methods a more invasive procedure
is used (e.g., blood sample or biopsy). Various imagingmoda-
lities can be used for tumor visualization such as fluorescent
imaging, magnetic resonance imaging (MRI) or radionuclide
imaging with positron emission tomography (PET), or single
photon emission computed tomography (SPECT). In most
cases, the use of PET is preferred over SPECT since higher
spatial resolution images can be obtained and images can be
analyzed quantitatively more accurately with PET. Specific
uptake of molecular biomarkers can be achieved using
radiolabeled targeting agents such as antibodies, directed
against tumor-associated antigens like epidermal growth
factor receptor (EGFR) [2], human epidermal growth factor
receptor 2 (HER2), andmany others.The high specificity and
affinity of radiolabeled antibodies make them attractive can-
didates as an imaging agent. For example, 89Zr-labeled anti-
HER2 antibodies can be used to differentiate betweenHER2+
and HER2− tumors [3], also appreciating intra- and inter-
tumoral heterogeneity. An additional application of radiola-
beled antibodies is to identify patients who may benefit from
a particular therapy and monitor therapy outcome based on
the level of tumor-associated antigen expression [4]. How-
ever, the relative slow pharmacokinetics of intact antibodies
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= 3-4 days) requires the use of radionuclides with long
half-lives (e.g., 111In (2.8 days) for SPECT or 89Zr (3.3 days)
and 124I (4.2 days) for PET [5]). For antibody based PET
imaging (immune-PET) 89Zr has several advantages: 89Zr has
a half-life of 78.4 h which matches the pharmacokinetics of
antibodies and it has a relative low average positron energy of
395 keV, making it an ideal candidate for high resolution PET
imaging of slow-accumulating biomolecules. In addition,
89Zr-based agents are safer to handle and more stable in vivo
making them better candidates than 124I-based agents for
clinical applications. Due to the numerous advantages of
89Zr-based immuno-PET, the field is progressing at a rapid
and exciting pace. In this review, the potential of 89Zr-based
immuno-PET in oncology will be reviewed. The production
of 89Zr, the bioconjugation strategies, and applications in
(pre-)clinical studies are discussed.
2. Radiochemical Properties of 89Zr
89Zr decays (half-life of 78.4 h) first via positron emission and
electron capture to 89mY (half-life of 15.7 s) which in turn
decays via gamma ray emission (909 keV) to the stable 89Y.
With its relatively low energy positrons (average energy
395 keV) 89Zr provides high resolution PET images. In addi-
tion, the energy disparity between the photons (511 keV) and
the gamma rays (909 keV) prevents the latter from interfering
with the detection of 511 keV photons. In contrast, its halogen
competitor, 124I, produces high energy photons of different
energies (603 keV (63.0%), 1691 keV (10.9%), and 723 keV
(10.4%) [6]) which may result in random and scatter coinci-
dences and therefore in more background noise as compared
to 89Zr. Hence, reconstruction of 89Zr-based PET scans is
more straightforward to attain good image quality compared
to 124I. Although 89Zr has many advantages over other PET
radionuclides, some essential shielding requirements during
transport and handling of 89Zr are needed (half-value layer
of 89Zr in lead is roughly 10mm). High energy and highly
penetrating photons (909 keV) are emitted during 89Zr decay
in high abundance.
3. Production of 89Zr
The first production of 89Zr was done by Link et al. [7] by
a (p,n) nuclear reaction by bombarding 89Y on Y foil with
13MeV protons [5].The produced 89Zr needed several purifi-
cation steps andwas obtained in 80% yield with radionuclidic
purity exceeding 99%. Nowadays, many medical centers are
able to producemedical isotopes using low-energy cyclotrons
that are capable of bombarding targets with protons of low
energy (<20MeV). Therefore, the most common route to
produce 89Zr is via the 89Y (p, n) 89Zr reaction on commer-
cially available 89Y target foils.The above route will in general
result in high yields (94-95%) and high radionuclidic purities
(>99%). Competing nuclear reaction, like (p, 2n) reactions,
can result in small amounts radionuclidic byproducts, such
as 88Zr and 88Y [8]. Several separation and purification
techniques with variable outcomes are used including anion
exchange, cation exchange, and solvent extraction [9–11]. For
synthesizing such radiopharmaceuticals for patients, auto-
mated units for a clean, fast, safe, and reproducible radionu-
clide synthesis according to good manufacturing practice
(GMP) are necessary. Several groups have designed and built
automated systems for 89Zr [12, 13]. For exampleWooten et al.
[14] reported a custom-made system to safely and routinely
produce 89Zr with high radionuclidic purity (>99.99%) and
satisfactory effective specific activity (5–353 mCi⋅𝜇mol−1
(0.01%–0.88%of theoretical specific activity)) based on previ-
ous developments in separation and purification techniques
[9–11, 15].
4. The Need for Efficient Chelators
The release of 89Zr4+ from the antibodies needs to be pre-
vented, because the free radionuclide can accumulate in the
mineral bone and can associate with plasma proteins. This
leads to depositing significant doses to the bone marrow [16].
Therefore, an appropriate chelator system is necessary tomin-
imize the disassociation of 89Zr from the antibodies. Over the
years, several chelators have been used with different suc-
cess, such as diethylenetriaminepentaacetic acid (DTPA),
ethylenediaminetetraacetic acid (EDTA), 1,4,7,10-tetraacetic
acid (DOTA), and desferoxamine (DFO) [17].The stability of
Zr-DOTA, Zr-DTPA, and Zr-EDTA was found to be limited.
The thermodynamic stability of Zr-DTPA is slightly higher
than that of Zr-EDTA, most likely because DTPA coordi-
natively saturates the Zr4+, while EDTA requires exogenous
water molecules [18]. DFO is the most prominent chelator
of Zr4+. DFO is a hexadentate siderophore containing three
hydroxamate groups for chelating metals and a primary
amine tail for conjugation to a biomolecule (Figure 1). Besides
a zirconium chelator, it is a chelating agent for several other
metal ions [19]. It demonstrated good stability, releasing less
than 0.2% of Zr4+ after 24 h in serum [20] and after seven days
in serum still less than 2% demetallation occurs [21]. Several
proof-of-principle preclinical studies have been conducted
using DFO to label antibodies with 89Zr; however, the in vivo
stability of this complex remains an issue, because free 89Zr is
observed in the bone dependent on the in vivo behavior of the
antibody [22]. Several studies have attempted to improve the
linkage between DFO and the antibody [9, 23], whereas oth-
ers have focused on improving the chelate itself [24]. Even-
tually, a ligand that is both octadentate and oxygen-rich is
believed to be the most stable Zr4+ chelator, since it would be
able to incorporate all eight coordination sites of zirconium
[22]. This novel high stability Zr4+ ligand would in theory
minimize the uptake of liberated Zr4+ in the bone and other
nontargeted tissues. To date, the design, synthesis, and the
evaluation of such a Zr4+ chelate requires further research.
4.1. Conjugation of Antibodies withDFO. AsDFO is currently
the most promising chelator for 89Zr4+, conjugation of anti-
bodies with DFO will be discussed here in detail (Figure 1).
Several methods are available to conjugate DFO based on
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Figure 1: Schematic overview of 89Zr-labeled antibody using DFO as chelator.
the reaction of an activated bifunctional chelator with a lysine
or cysteine residue of the antibody. The different conjugation
techniques do not only have different conjugation efficiencies,
but also affect the biodistribution of the radiolabeled anti-
body [22].
The earliest reports on conjugation of DFO to bioactive
molecules is based on the addition of thiols to the amino
group ofDFO [20]. In this approachDFOwasmodified byN-
succinimidyl-S-acetylthioacetate (SATA), resulting in an S-
acetyl-protected thiol derivatized formof chelator. In parallel,
maleimide moieties were introduced in the antibody by
the reaction with 4-(N-maleimidomethyl) cyclohexane car-
boxylic acid N-hydroxysuccinimide ester (SMCC). Next, the
two formed compounds were combined and in the presence
of hydroxylamine at physiological pH the DFO-antibody
conjugate was formed. Following this early work, Verel et al.
introduced a novel conjugation approach, which was based
on an activated 2,3,5,6-tetrafluorophenol (TFP) chelate ester
which can form a stable amide bondwith the 𝜀-amino-groups
of the lysine residues of the monoclonal antibody (mAb) [9].
This laborious approach consisted of 5 steps which involve (i)
the extension of DFOwith succinyl anhydride, (ii) protection
of side-reactions of the hydroxamate groups of the ligand
by complexation with Fe3+, (iii) formation of activated TFP
ester, (iv) conjugation of activated DFO-ester to the unmod-
ified antibody, and (v) removal of Fe3+ from the chelator.
Nowadays the most widely used method in preclinical 89Zr-
based immuno-PET uses the conjugation strategy with N-
succinimidyl-DFO,which addresses 𝜀-amino groups of lysine
side chains [22, 25–30]. Since the Zr4+ field is rapidly growing
and becomingmoremainstream in the clinical setting, simple
methods for DFO conjugation preferably using commercial
available starting materials are essential. Perk et al. intro-
duced a simplified method using a commercially available
p-isothiocyanatobenzyl-DFO (DFO-Bz-NCS) chelate, which
can be directly attached to the 𝜀-aminogroups of the lysine
residues of an antibody by forming a stable thiourea linkage
[23]. Despite the fact that this method is simpler than the
N-succinimidyl-DFO chemistry, it requires more expertise
mainly because of the limited water solubility of the chelator
precursor.
A limitation of the conjugation of DFO to antibodies is
compromised immunoreactivity, because the chelator may
interfere with the antigen-binding domain of the antibody,
especially if there are lysines in or close to the complemen-
tarity determining regions of the antibody. To overcome these
limitations site-specific strategies using engineered cysteine
residues can be used in combination with thiol-reactive DFO
derivatives such as bromoacetamido-desferrioxamine (DFO-
Bac), iodoacetamido-desferrioxamine (DFO-Iac), and male-
imidocyclohexyl-desferrioxamine (DFO-CHX-Mal) [31].
The radiolabeled antibodies using these thiol-reactive DFO
derivatives were stable and showed similar characteristics
as the lysine-linked complexes. Remarkably, no significant
difference was observed between the immunoreactivity of the
site-specific complex and the lysine-linked complexes.
Another novel conjugation approach for effective labeling
of 89Zr to antibodies is the use of click chemistry between an
acetylene group and an azide.This approachmight not signif-
icantly improve the targeting of tumors compared with DFO-
based conjugation strategies; however, with this approach it
is possible to fully tailor the constructs. Furthermore, the
modular system can be used for direct comparison of bio-
conjugates with different radiometals as the the chelator-
modified antibodies are synthesized using identical ligation
conditions resulting in similar immunoreactivity and chela-
tor/antibody ratios [32]. Several studies have been reported
on bioorthogonal click chemistry [32], Staudinger ligation
[33], or catalyst-free click chemistry [34].The click chemistry
as specialized conjugation method is expected to expand the
scope of 89Zr-based PET.
5. Preclinical Studies with 89Zr
Over the last years several 89Zr-labeled antibodies directed
against different tumor types have been evaluated in preclin-
ical studies (e.g., [9, 18, 22, 35, 36]; see Table 1). Here these
developments of 89Zr-labeled antibodies in preclinical studies
will be discussed based on their tumor target.
5.1. Targeting CD20. The glycosylated phosphoprotein,
CD20, is expressed on the surface of B-cell lymphomas, hairy
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Table 1: Overview of the described preclinical and clinical studies using 89Zr-labeled antibodies.
Target Type of tumor Targeting vector
CD147 Pancreas 059-053
CD20∗ Non-Hodgkin’s lymphoma ibritumomab tiuxetan
CD44v6∗ Head and neck squamous cell carcinoma cmAb U36
EGFR Multiple Cetuximab
EGP-1 Prostate hRS7
GPC3 Liver 𝛼GPC3
HER1 Colorectal Panitumunmab
HER2∗ Breast and ovarian Trastuzumab
IGF-1R Triple negative breast cancer R1507
MET Head and neck squamous cell carcinoma and gastric DN30
MN/CA IX Renal cell carcinoma cG250
PSMA Prostate 7E11
PIGF Liver RO5323441
VEGF∗ Breast, head, and neck squamous cell carcinoma and ovarian Bevacizumab
∗Targets evaluated in clinical studies.
leukemia, B-cell chronic lymphocytic leukemia, and mela-
noma cells. 89Zr-labeled antibodies directed against CD20
might be useful tomeasure andmonitor the therapeutic effect
of non-Hodgkin’s lymphoma (NHL) therapy [18, 37]. The
89Zr-Desferrioxamine-rituximab, an antibody directed
against CD20, specifically targeted the human CD20 antigen
in a humanized CD20-expressing transgenic mouse model
(huCD20TM). 90Y-labeled anti-CD20 mAb ibritumomab
tiuxetan (Zevalin) is approved for treatment of patients with
relapsed and refractory NHL. In a pilot study, 89Zr-labeled
ibritumomab tiuxetan was shown to have a nearly identical
biodistribution compared to 90Y-labeled counterpart [18].
This indicated that a scout scan with 89Zr-ibritumomab
immuno-PET can be used to assess, predict, and quantify the
biodistribution of 90Y-ibritumomab tiuxetan.
5.2. Targeting CD44. The cell-surface glycoprotein, CD44, is
involved in many biological processes including adhesion of
cells to extracellular matrix proteins, lymphocyte-endothelial
cell interactions,metastasis formation,migration of cells, and
T cell activation/adherence [38]. The v6 splice variant of
CD44 is involved in tumorigenesis, tumor cell invasion, and
metastasis and is expressed preferentially in squamous cell
carcinomas [39]. Preclinical studies using 89Zr-labeled anti-
CD44v6 chimeric monoclonal antibody cU36 demonstrated
that the tracer was able to detect small tumors in nude mice
with HNSCC xenografts [9, 40]. In addition, it was reported
that 89Zr-cU36 PET imaging was a suitable candidate
for scouting of therapeutic doses of 90Y-cU36 [40, 41].
Recently, evaluation of 89Zr-RG7356, an antibody directed
against the constant part of CD44, was performed in mice
bearing tumor xenografts with different levels of CD44
expression and RG7356 responsiveness, namely, MDA-MB-
231 (CD44+, responsive), PL45 (CD44+, nonresponsive), and
HepG2 (CD44−, nonresponsive) [42]. 89Zr-RG7356 selec-
tively targeted CD44+ responsive and nonresponsive tumors
in mice. 89Zr-RG7356 whole body immuno-PET in healthy
cynomolgus monkeys revealed antibody uptake in spleen,
salivary gland, and bone marrow, which might be related to
the expression of CD44 in these organs. The 89Zr-RG7356
uptake in the normal organs decreased with increasing dose
of unlabeled RG7356, indicating saturable targeting of CD44
in these animals.
5.3. Targeting EGFR. The epidermal growth factor receptor
(EGFR) is a member of the ErbB family. It plays a crucial role
in differentiation, proliferation, and survival of many differ-
ent tumor types, including breast, lung bladder, and colon
carcinoma [2].The overexpression of EGFR is associatedwith
more aggressive tumors and poor prognosis due to the resis-
tance of treatment [43, 44]. ManymAbs have been developed
to inhibit the EGFR activation [2]. A well-known example
is cetuximab (Erbitux), a chimeric IgG, which upon binding
to the ligand-binding domain induces internalization of
EGFR and thereby blocking downstream signalling [45, 46].
Several studies showed tumor regression upon treatment
with cetuximab [47–50].
89Zr-labeled cetuximab was evaluated for scouting the
biodistribution of 90Y- and 177Lu-cetuximab in tumor bear-
ing mouse and thus potentially allowing the estimation of the
radiation dose delivered to tumors and normal tissues during
radioimmunotherapy with 90Y- and 177Lu-cetuximab [51]. It
was reported that the 89Zr-immuno-PET could be used for
in vivo scouting of 90Y- and 177Lu-labeled mAbs. However,
an increased bone uptake of 89Zr-cetuximab, compared with
90Y- and 177Lu labeled cetuximab, was observed indicating
that 89Zr is more efficiently incorporated in the bone com-
pared to the other radiometals (90Y- and 177Lu). Therefore
estimating bone marrow doses based on 89Zr-bone uptake is
not straightforward. Another study investigated the relation
between the in vivo expression of EGFR and the tumor
uptake of 89Zr-cetuximab [52]. In this study no clear-cut
relationship was found, suggesting that apart from antigen
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Figure 2: Specificity of 89Zr-trastuzumab for HER2-positive tumors. Coronal 89Zr-trastuzumab, 18F-FDG, and 18F-FLT PET images of
athymic nude mice bearing subcutaneous HER2-positive NCI-N87 (left) and HER2-negative MKN-74 (right) are shown. ROIs (%ID/g) for
89Zr-trastuzumab, 18F-FDG, and 18F-FLT are indicated. +ve = positive; −ve = negative. This research was originally published in [3]. © by the
Society of Nuclear Medicine and Molecular Imaging, Inc.
expression other parameters determine the tumor uptake of
89Zr-cetuximab.
Another approved mAb to inhibit the EGFR signalling
is panitumumab. It was the first recombinant human mon-
oclonal antibody (IgG2) approved by the FDA for the treat-
ment of patients with EGFR-expressing metastatic colorectal
cancer (mCRC) [53]. In several studies the use of panitu-
mumab for noninvasive, in vivo imaging of HER1 expression
in tumors is reported [54–58].The use of 89Zr-panitumumab
for immuno-PET of HER1 expression was recently evaluated
in a direct comparison with 111In-panitumumab. The organ
biodistribution between 111In- and 89Zr-panitumumab was
almost identical [55]. In addition, the targeting of 89Zr-
panitumumab correlated well with the HER1 expression.
Recently, a standardized and straightforward stepwise ∼5 h
production method was reported for the production of
clinical-grade 89Zr-panitumumab [59]. In this method
clinical-grade panitumumab is conjugated with DFO chelate
and subsequently radiolabeled with 89Zr resulting in high
yields (>70%) and high radiochemical purity (>98%).
5.4. Targeting HER2. Human epidermal growth factor recep-
tor 2 (HER2) is another member of the ErbB family. It is
involved in angiogenesis, differentiation, metastasis, prolifer-
ation, and cell survival upon heterodimerization with other
members of the EGF receptor family [60]. HER2 overex-
pression is found in many types of tumors including breast
and ovarian cancer. The FDA approved anti-HER2 mAb
trastuzumab (Herceptin, Genentech, CA,USA) to be used for
the treatment of HER2 positive breast tumors, since it blocks
the HER2 activation [60]. The efficacy of the treatment is
dependent on the HER2 expression level. The HER2 expres-
sion level in a tumor is not static and may vary over time
[60]. In addition, theHER2 expression is found to be different
between the primary lesion and the distant metastatic lesions
in the same patient. Noninvasive in vivo imaging to visualize
HER2 expressing using radiolabeled trastuzumab has been
extensively investigated [29, 30, 61]. PET imaging using
89Zr-trastuzumab has been performed in different murine
tumor models and accumulation of the tracer was found to
be HER2 specific [29, 30, 61]. For example, the tumor uptake
of 89Zr-trastuzumab in nude mice with a subcutaneous
human ovarian cancer xenografts (SK-OV-3) was high
(∼30% ID/g) and the biodistribution was similar to that
of 111In-trastuzumab [29]. Recently, the specificity of 89Zr-
trastuzumab, 18F-FDG, and 18F-FLT PET for HER2-positive
gastric cancer was evaluated ([3]; Figure 2). The study
revealed a high specific uptake of 89Zr-trastuzumab inHER2-
positive tumors, whereas 18F-FDG and 18F-FLT PET were
unable to differentiate between HER2-positive and HER2-
negative tumors. In addition, 89Zr-trastuzumab was used to
quantitatively determine the HER2 expression level after
treatment. For example, after treatment with a heat shock
protein 90 (hsp90) inhibitor a significant decrease in HER2
expression could bemeasured based on the 89Zr-trastuzumab
tumor targeting [30, 62]. A combination treatment of
hsp90 inhibitor 17AAG and the EGFR/HER2 tyrosine kinase
inhibitor, lapatinib, revealed an even stronger reduction of the
HER2 expression levels using 89Zr-Trastuzumab-F(ab󸀠)
2
fragment as probe [63]. Additionally, the biological effect of
afatinib, an EGFR/HER2/HER4 inhibitor, in aHER2-positive
gastric xenograft models was evaluated [3]. In this model the
uptake of 18F-FDG did not change after afatinib therapy,
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whereas a decrease in 89Zr-trastuzumab uptake was observed
upon treatment. The lower uptake of the 89Zr-trastuzumab
correlated with the decreased HER2 expression as deter-
mined by immunoblots and immunohistochemistry. Thus,
89Zr-trastuzumab PET might be useful for the characteriza-
tion, treatment planning, and treatment monitoring of HER-
2 positive cancers.
5.5. Targeting VEGF. Vascular endothelial growth factor
(VEGF) is a proangiogenic factor in both normal tissues and
in tumors. The overexpression of VEGF and its receptors
(VEGFR) are associated with poor prognosis [64]. The
humanized anti-VEGF mAb, bevacizumab (Avastin,
Genentech/Hoffmann-La Roche), is capable of blocking
angiogenesis by depleting VEGF and thereby preventing its
binding to the VEGFR. This neutralizes VEGF actions (see,
e.g., [65–72]). A direct comparison between 89Zr-
bevacizumab and an irrelevant 89Zr-labeled IgG revealed a
significantly higher tumor uptake of 89Zr-bevacizumab in
nude mice with human ovarian SK-OV-3 tumors [73].
Besides using 89Zr-bevacizumab as PET tracer for non-
invasive in vivo imaging of VEGF expression in the tumor
microenvironment, potentially it can also be used to predict
ormonitor an antiangiogenic response. For example, hsp90 is
crucial player in VEGF transcription and can be used to treat
ovarian tumors. In nude mice with a subcutaneous human
ovarian cancer xenografts (A2780), uptake of 89Zr-
bevacizumab in the tumors correlated with the therapeutic
effect of the hsp90 inhibitor, NVP-AUY922, [74]. In another
study the effect of the mTOR inhibitor, everolimus, on the
VEGF production was evaluated [75]. Everolimus treatment
caused decreased 89Zr-bevacizumab uptake in subcutaneous
A2780 human ovarian tumor. The results were in line
with the lower VEGF-A protein levels in tumor lysates of
treated versus untreated tumors. These results indicate 89Zr-
bevacizumab can be used to monitor tumor VEGF-A levels
as an early biomarker of the antiangiogenic effect of mTOR
inhibitor treatment.
89Zr-labeled ranibizumab, a monoclonal antibody frag-
ment (Fab) derivative of bevacizumab, was used to detect and
monitor the early antiangiogenic response to treatment with
sunitinib, a VEGFR tyrosine kinase inhibitor, in nude mice
bearing a subcutaneous A2780 human ovarian tumor or
Colo205 human colon cancer xenografts. 89Zr-ranibizumab
PET matched better with the observed results obtained by
histology, immunohistochemistry, and tumor proliferation
and vascularization assays, than 18F-FDGPET and 15O-water
PET. Since ranibizumab has a serum half-life of only 2 to 6
hours, rapid and sequential follow-up PET scans are feasible
with 89Zr-ranibizumab [76]. Therefore, in contrast to 89Zr-
bevacizumab, 89Zr-ranibizumab can be used for imaging of
rapid dynamic alterations in VEGF response in tumors.
5.6. Targeting PIGF. The clinical benefits of angiogenesis
inhibitors can be compromised by the upregulation of
proangiogenic factors such as the placental growth factor
(PIGF). PIGF, a VEGF homolog, is expressed in low levels in
normal tissue and can be overexpressed in tumor cells. PIGF
contributes to angiogenesis in pregnancy, wound healing,
ischemic conditions, and tumor growth [77, 78]. PIGF
inhibitors are able to reduce the angiogenesis and tumor cell
motility.The antitumor activity of a humanizedmAbdirected
against PIGF-1 and PIGF-2, RO5323441, in human tumor
xenograft models has been reported [79]. To further explore
and validate the use of RO5323441, the tumor and normal
tissue uptake of 89Zr-RO5323441 at different time points was
evaluated in mice bearing human PlGF-expressing Huh7
hepatocellular cancer xenografts. Tumor accumulation of
89Zr-RO5323441 was specific and time- and dose-dependent.
5.7. Targeting PSMA. Prostate-specific membrane antigen
(PSMA) is a transmembrane glycoprotein which is associated
with increased tumor progression, development of castration
resistance, and/or resistance to hormone-based treatments
[80–82]. PMSA is expressed in a limited range of normal
tissues including benign prostatic epithelium, renal proximal
tubule, small bowel, and the brain; however, the expression
level is 2 to 3 times lower than in prostate cancer speci-
mens [83]. 89Zr-labeled anti-PSMA mAb, J591, was able to
differentiate between subcutaneous PSMA positive and neg-
ative tumors in athymic nude mice [21], making it a potential
target for clinical noninvasive identification and quantifica-
tion of PSMA-positive tumors.
5.8. Targeting CD147. CD147, a member of the immunoglob-
ulin superfamily, is involved in many physiological functions
including embryo implantation, early stage neural network
formation, and spermatogenesis [85]. Overexpression of
CD147 is found in many types of cancer including pancreatic
cancer and induces expression of matrix metalloproteinases
(MMPs) and VEGF [86, 87]. Several (pre-)clinical studies
have been performed using anti-CD147 antibodies to inhibit
the actions of CD147 and revealed a reduction in prolifera-
tion, invasion andmetastasis of tumors [88–90]. Almost 90%
of the pancreatic cancers have high CD147 expression levels
[86]. Sugyo et al. evaluated the CD147 expression in four
pancreatic cancer cell lines (MIA Paca-2, PANC-1, BxPC-3,
and AsPC-1) using the human 125I-, 67Ga-, or 89Zr-labeled
anti-CD147 mAb (059-053) [84]. Additionally, the in vivo
CD147 expression was evaluated using 125I- or 89Zr-labeled
059-053 in mice with s.c. and orthotopic MIA Paca-2 and
A4 (non-CD147-expressing) tumors.Thebiodistribution data
revealed significantly higher tumor uptake of 89Zr-059-053
in MIA Paca-2 tumors than in the A4 tumors (Figure 3).
PET/CT imaging demonstrated that orthotopic MIA Paca-2
tumors could be visualized with 89Zr-059-053 PET. High
expression of CD147 is not only restricted to pancreatic
cancer, but is also found in other types of cancer including
bladder, breast, colorectal, cervical, liver, and ovarian cancer
[84–86]. Therefore, 89Zr-059-053 might also be applied in
patients with these cancer types.
5.9. Targeting CAIX. Hypoxia in tumors is associated with a
poor prognosis inmany tumor types since it is associatedwith
resistance to radiotherapy and chemotherapy. Inmany tumor
types carbonic anhydrase IX (CAIX) has been validated as
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Figure 3: In vivo biodistribution experiments in nude mice bearing MIA PaCa-2 and A4 xenografts of radiolabeled anti-CD147 antibody
059-053. Samples were collected and weighted, and radioactivity was measured at days 1 (white bars), 2 (dot bars), 4 (gray bars), and 6 (black
bars) after intravenous injection of 37 kBq each of 89Zr-059-053 (a) and 125I-059-053 (b). Data are expressed as mean ± SD (𝑛 = 5). ∗𝑃 < 0.01
versus 89Zr-059-053 tumor uptake at each time point analyzed by ANOVA with the Student-Newman-Keuls method multiple comparison
test. This research was originally published in [84].
an intrinsic hypoxia-related cell marker [91]. Using antibod-
ies directed against CAIX it is possible to select patients
for hypoxia-targeting or -modifying treatment combined
with radiotherapy. For example, it is possible to visualize
tumor hypoxia in mice bearing s.c. SCCNij3 head and neck
squamous cell carcinomas using 89Zr-cG250-F(ab󸀠)
2
, an anti-
CAIX antibody fragment [92]. In a direct comparison, the
tumor uptake of mAb 89Zr-cG250 in mice with CAIX-
expressing clear cell renal cell carcinoma (ccRCC) xenografts
(NU-12) was significantly higher compared to that of 124I-
cG250 [93].This indicates that PET imaging of ccRCC tumors
with 89Zr-cG250 could be more sensitive than 124I-cG250-
PET. CAIX targeted 89Zr-PET imaging is a candidate for
imaging hypoxia in different types of tumors and deserves
further exploration.
5.10. Targeting IGF-1R. The insulin like growth factor 1
receptor (IGF-1R) is a transmembrane receptor expressed in
many human cancers, including in∼35% of all triple-negative
breast carcinomas. It is involved in the proliferation, apop-
tosis, angiogenesis, and tumor invasion. Heskamp et al.
reported excellent tracer uptake of 111In-R1507 and 89Zr-
R1507, a human mAb directed against IGF-1R, in mice with
s.c. SUM149 triple-negative breast cancer xenografts [94].
This suggests that the use of 89Zr-R1507 in patient selection
of IGF-1R-targeted therapy is possible.
5.11. Targeting Met. The expression of hepatocyte growth
factor receptor tyrosine kinase (Met) was measured by PET
using 76Br or 89Zr-labeled-onartuzumab, a mAb against Met
[95]. Both tracers specifically targeted Met; however, at later
time points a higher tumor uptake was observed with 89Zr-
Onartuzumab. This suggests that 89Zr-onartuzumab is the
preferred tracer to identify Met expression in cancer patients
and possibly to predict and monitor the treatment with
Met-targeted therapeutics. In another study, the potential
of immune-PET using 89Zr (residualising radionuclide) or
124I-labeled (non-residualising radionuclide) anti-Met mAb
DN30 was evaluated in mice with s.c. GLT-16 (high Met
expression) and FaDu (low Met expression) tumors [96].
The biodistribution data revealed significantly higher tumor
uptake of 89Zr-DN30 than 124I-DN30 in GTL-16 tumor-
bearing mice. Similar blood levels were found indicating that
DN30 is internalized. 89Zr-DN30 immuno-PET imaging was
able to visualize small tumor lesions with a higher 89Zr tumor
uptake in GTL-16 than FaDu tumor-bearing mice. Addition-
ally, the correlation was high for PET-image-derived 89Zr
tumor uptake and the ex vivo-assessed 89Zr tumor uptake.
This indicates that 89Zr-labeled immuno-PET is an attractive
method to evaluate Met-targeted therapeutics.
5.12. Targeting GPC3. The glypican-3 (GPC3) is a hepato-
cellular-specific cell surface proteoglycan overexpressed in
most hepatocellular carcinomas (HCC). Sham et al. reported
excellent tracer uptake of 89Zr-𝛼GPC3, a mAb directed
against GPC3, in mice with GPC3-expressing HepG2 liver
tumors [97]. This suggests that the use of 89Zr-𝛼GPC3 to
image HCC in the liver is possible.
6. Clinical Translation of 89Zr Immuno-PET
The 89Zr-labeled antibodies against the targets mentioned
above all show promising results for clinical translation. To
date, several clinical investigations using 89Zr-labeled anti-
body constructs have been reported [1, 22, 98]. Here these
recent clinical studies will be discussed.
6.1. 89Zr-Labeled cU36. The first clinical trial using the 89Zr-
cU36 PET to target CD44 expressing tumors showed that
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the tracer was able to detect primary tumors as well as
metastases in the neck region with similar sensitivity as com-
puted tomography (CT) and magnetic resonance imaging
(MRI) [99].The results are promising, although several issues
remain to be addressed. In the clinical studymicrometastases
were missed with 89Zr-cU36 PET, so immuno-PET may be
less suited as a staging tool, but more suitable to characterize
tumors.Moreover, 2 out of the 20 patients developed antibod-
ies against the chimeric cU36 antibody (HACA), which may
hinder repetitive imaging procedures.
6.2. 89Zr-Ibritumomab. A clinical prospective study was con-
ducted to evaluate the biodistribution and radiation dosime-
try of CD20-targeting 90Y-ibritumomab tiuxetan using 89Zr-
ibritumomab tiuxetan [100]. Patients with relapsed or refrac-
tory aggressive B-cell (CD20-positive) NHL underwent a
PET scan at 1, 72 and 144 h after injection of 70MBq 89Zr-
ibritumomab tiuxetan and again 2 weeks later after coin-
jection of 15MBq/kg or 30MBq/kg 90Y-ibritumomab tiuxe-
tan. The results revealed that simultaneous therapy of 90Y-
ibritumomab tiuxetan did not affect the biodistribution of
89Zr-ibritumomab. A second aim of the study was to estimate
the radiation doses during radioimmunotherapy with 90Y-
ibritumomab tiuxetan based on 89Zr-ibritumomab PET. The
highest 90Y absorbed dose was observed in liver (3.2 ±
1.8mGy/MBq) followed by the spleen (2.9 ± 0.7mGy/MBq).
Additionally, the correlation was high for standardized
uptake value (SUV) of 89Zr-ibritumomab tiuxetan and
absorbed dose of 90Y-ibritumomab tiuxetan in the liver at 72 h
p.i. and 144 h p.i.This suggests that in the future a single 89Zr-
ibritumomab tiuxetan PET scan is sufficient to optimize the
administered amount of 90Y-ibritumomab tiuxetan RIT for
individual patients
6.3. 89Zr-Trastuzumab. In 2010, the first-in-man report of
89Zr-trastuzumab for imaging of HER2-positive lesions in
patients with metastatic breast cancer was published [101].
14 Patients were included in the study that either received 10
(𝑛 = 2) or 50 (𝑛 = 5) mg 89Zr-trastuzumab if trastuzumab-
na¨ıve and 10mg 89Zr-trastuzumab (𝑛 = 7) if on trastuzumab
treatment (37MBq 89Zr-trastuzumab). Per patient at least
two PET scans were acquired between day 2 and day 5
after injection of 89Zr-trastuzumab. The trastuzumab-na¨ıve
patients required a 50mg dose for effective imaging whereas
10mg was sufficient in the trastuzumab-treated patients. A
higher dose in the trastuzumab-na¨ıve patients was required
as an increased 89Zr-trastuzumab clearance was observed
at lower doses due to presence of extracellular domains of
the HER2 receptor in the circulation [102]. After binding of
89Zr-trastuzumab to these extracellular domains, the
immune complex was cleared by the liver and excreted in
the intestines. In patients treated with trastuzumab at the
time of injection, higher doses of 89Zr-trastuzumab did not
improve imaging since complex formation was minimal.
Overall, the uptake of 89Zr-trastuzumab in the tumor lesions
was high. The best time to assess tumor uptake was 4 to
5 days after injection of 89Zr-trastuzumab (Figure 4). All
the known and even some unknown lesions were detected
with PET. Of interest, metastatic brain lesions were detected
in several patients, despite the fact that trastuzumab cannot
penetrate the blood-brain barrier. This is probably because
the blood-brain barrier in patients with brain metastasis is
disrupted allowing 89Zr-trastuzumab to pass. In this study
HER2 overexpressing lesions could be distinguished
from non-HER2 expressing lesions. These data indicate the
potential use of 89Zr-trastuzumab to improve the diagnosis of
patients with HER2-positive breast cancer especially when
lesions are inaccessible for biopsy.
6.4. 89Zr-Bevacizumab. Recently, a clinical study was per-
formed to assess the use of 89Zr-bevacizumab for the visu-
alization of VEGF-A in primary breast cancer [103]. In 23
patients, 26 tumors were detected by conventional imaging
modalities mammography (𝑛 = 22), ultrasound (𝑛 = 25), or
MRI (𝑛 = 1). Prior to surgery and 4 days p.i. of 37MBq of
89Zr-bevacizumab the patients underwent a PET/CT scan of
the breasts and the axillary regions (Figure 5(a)). 25 of the
26 breast cancer nodules (96.1%) were detected using 89Zr-
bevacizumab. Also, a correlation between the VEGF-A pro-
tein level in the tumors observed as measured by VEGF-
A ELISA and the tumor uptake 89Zr-bevacizumab was
found (Figure 5(b)). This study provides evidence that 89Zr-
bevacizumab might be a potential candidate for the classifi-
cation of breast tumors and to predict and monitor the effect
of VEGF-A targeted therapies.
7. Conclusions
Clinical studies revealed that the use of 89Zr-based immuno-
PET results in high spatial resolution images with high tumor
uptake and a good signal to noise ratio. Therefore, the use of
89Zr-labeled antibodies is very promising for noninvasive
visualization of tumor-associated antigens before, during,
and after therapy. This makes 89Zr-based immuno-PET an
excellent imaging modality to predict and monitor treatment
and to tailor treatment for individual patients. However, to
fully integrate 89Zr-based immuno-PET in the clinic several
hurdles still need to be overcome. For example, standard-
ized and robust methods for stable conjugation of DFO to
antibodies should become available to obtain clinical-grade
conjugates. In addition, research should focus on the devel-
opment of improved chelators to minimize the amount of
liberated Zr4+. Although some direct comparison studies
between 89Zr-based immuno-PET and immuno-PET using
other PET isotopes have been performed, and supplementary
quantitative and comprehensive comparison studies are
needed to evaluate the value of 89Zr-based immuno-PET.
Additionally, the radiation dose for patients undergoing a
89Zr-based immuno-PET (75MBq of 89Zr-cmAb U36) was
found to result in a mean effective dose of 0.53 to
0.66mSv/MBq [104] which is significantly higher compared
to themean effective dose of clinically used 111In- and 99Tcm-
based tracers (111In-IgG (75MBq) was 0.25mSv/MBq and
99Tcm-IgG (750MBq) was mu Sv/MBq) [105]. The high
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Figure 4: Examples of 89Zr-trastuzumab uptake 5 days after the injection: (a) a patient with liver and bone metastases and ((b) and (c)) two
patients withmultiple bonemetastases. A number of lesions have been specifically indicated by arrows.This research was originally published
in [101].
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Figure 5: (a) Axial slices of 89Zr-bevacizumab PET frompatient with primary breast tumor (1) and lymph nodemetastasis (2). (b) Correlation
between 89Zr-bevacizumab tumor uptake (𝑥-axis) and tumor VEGF-A (𝑦-axis) levels as measured by ELISA (Pearson 𝑟 = 0.49, 𝑃 = 0.04).
This research was originally published in [103]. © by the Society of Nuclear Medicine and Molecular Imaging, Inc.
radiation dose for patients will limit repeated application of
89Zr-based immuno-PET [104]. However, introducing new
PET/CT scanners to allow better-quality immuno-PET
images to be obtained with a lower 89Zr radioactivity
(37MBq) dose have reduced the radiation dose [102, 103].
Furthermore, research is focusing on combining 89Zr-based
immuno-PET with other imaging modalities. For example,
the use of 89Zr-immuno-PET in combination with near-
infrared fluorescence (NIRF) imaging has been reported by
several groups [106–108]. The ongoing development of new
89Zr-labeled antibodies directed against novel tumor targets
is believed to rapidly expand applications of 89Zr-labeled
immuno-PET to a valuable method in the medical imaging.
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